MedTrace Logo

Study of Ruxolitinib Cream in Children With Atopic Dermatitis

NCT05034822 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2023-09-15

No results posted yet for this study

Summary

This is an open-label maximum use trial to evaluate ruxolitinib safety, tolerability and blood levels after its topical application twice daily to affected areas (≥ 35% BSA) in pediatric participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse events.

Conditions

Interventions

DRUG

Ruxolitinib cream

Ruxolitinib 1.5% cream applied twice daily.

Sponsors & Collaborators

Principal Investigators

  • Haq Nawaz, MD, MPH, MBA, MS · Incyte Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-16
Primary Completion
2023-08-07
Completion
2023-08-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05034822 on ClinicalTrials.gov